Skip to content
How It Works
Explore
Ask a Question Resources Pricing
Who It's For
Patients
Decode results, prep for appointments, weigh options.
Caregivers & advocates
Carry the research load for someone you love.
Providers & clinicians
Resources for patients in your practice.
Log In Ask a Question
PubMed This is a summary of 41 peer-reviewed journal articles Updated
Neurology · Dentatorubral-pallidoluysian atrophy

Dentatorubral-pallidoluysian atrophy (DRPLA): A Patient Guide

At a Glance

DRPLA is a rare inherited brain disorder caused by an ATN1 gene expansion. Symptoms vary by age and may include seizures, balance and movement problems, learning difficulties, or changes in memory and behavior; genetic testing confirms the diagnosis, and supportive care helps manage symptoms.

Dentatorubral-pallidoluysian atrophy (DRPLA) is a rare, inherited neurological disorder that affects the way the brain sends and receives signals, leading to progressive changes in movement, thinking, and behavior [1]. For many families, the road to a diagnosis is long, partly because the condition is so rare outside of Japan and because it can mirror other, more common neurological diseases [2]. Understanding that this is a genetic condition—one that often runs in families—is the first step toward finding the right care and support [3].

At its core, DRPLA is caused by a genetic expansion in a single gene called ATN1 [4]. This genetic change causes the body to produce a version of a protein that is harmful to specific areas of the brain responsible for coordination and balance [5]. Because it is an autosomal dominant condition, it can be passed from one generation to the next, often appearing earlier or with different symptoms in children than in their parents—a phenomenon that makes each family’s experience with the disease unique [6]. Genetic counseling is highly recommended to help families navigate testing for relatives and understand reproductive options.

The way DRPLA looks and behaves depends heavily on when a person first begins to show symptoms [7]. In children and teenagers, it often presents with seizures and challenges in learning or development, while in adults, it more commonly begins with balance issues or changes in personality and memory [8][9]. Because these symptoms overlap with conditions like Huntington’s disease or various ataxias, a definitive genetic test is the only way to confirm a diagnosis and begin planning for the future [1].

While there is currently no cure to stop the progression of DRPLA, there is a great deal that can be done to manage it [3]. A dedicated team of specialists—including neurologists, physical therapists, speech-language pathologists, and nutritionists—can work together to proactively address seizures, maintain mobility, and ensure safety with swallowing and nutrition [10]. Focusing on these supportive measures allows families to protect quality of life and focus on the moments that matter most, guided by a community of researchers and advocates dedicated to finding better answers [11].

In this guide

5 chapters

01

Understanding Your Diagnosis: Validation and Orientation

Learn what a Dentatorubral-pallidoluysian atrophy diagnosis means: ATN1 CAG repeats, inheritance, anticipation, symptom patterns, and key care questions.

02

Symptoms and Presentation by Age of Onset

Learn how DRPLA symptoms differ by age of onset, from infantile developmental delay and juvenile seizures to adult ataxia, psychiatric changes, and dementia.

03

Biology, Genetics, and Diagnosis

Learn how DRPLA develops and is diagnosed, including ATN1 CAG repeat testing, MRI and EEG findings, borderline results, and conditions doctors rule out.

04

Standard of Care Treatment and Management

Learn how DRPLA is managed with supportive care, including seizure treatment, therapy, swallowing safety, feeding tubes, psychiatric care, and advance planning.

05

Progression, Milestones, and What to Expect

Learn what to expect as DRPLA progresses, including mobility milestones, life expectancy, seizure emergencies, aspiration risks, and early palliative care.

Common questions in this guide

What causes DRPLA?
DRPLA is caused by an expansion, or repeated stretch, in the ATN1 gene. It is usually inherited in an autosomal dominant pattern, meaning it can pass from an affected parent to a child.
What symptoms can DRPLA cause?
Symptoms vary with the age when the condition begins. Children and teenagers may have seizures and learning or developmental difficulties, while adults may first notice balance problems or changes in personality and memory. Movement and coordination can worsen over time.
How is DRPLA diagnosed?
DRPLA can resemble Huntington’s disease and other ataxias, so symptoms alone may not distinguish it. A genetic test that looks for the ATN1 expansion is the definitive way to confirm the diagnosis. Genetic counseling can help explain what testing means for the person and their family.
Can DRPLA be cured or treated?
There is currently no cure that stops DRPLA from progressing. Treatment focuses on supportive care, including managing seizures, maintaining mobility, and supporting safe swallowing and nutrition. A coordinated care team can adjust support as needs change.
Which specialists help care for someone with DRPLA?
A neurologist can help coordinate care, while physical therapists, speech-language pathologists, and nutritionists can address mobility, swallowing, and nutrition needs. Genetic counselors can help families understand testing and reproductive options.
Should family members consider genetic counseling or testing for DRPLA?
Because DRPLA can run in families and follows an autosomal dominant inheritance pattern, relatives may benefit from discussing genetic counseling with a qualified professional. Counseling can help families understand testing, implications for relatives, and reproductive options. Testing decisions are personal and should be made with professional support.

Questions to Ask Your Doctor

Curated prompts to bring to your next appointment.

  1. 1.What is the most important first step we should take to build a care team that understands DRPLA?
  2. 2.How can we connect with other families or patient organizations that specialize in this rare condition?
  3. 3.What is the best way to monitor and track my (or my family member's) symptoms over time so we can adjust care quickly?
  4. 4.Are there any specific research studies or patient registries we should consider joining?

Questions For You

Tap a prompt to share your answer — we'll use it plus this page's context to start a tailored conversation.

References

References (11)
  1. 1

    Overexpanded CAG repeats in ATN1 cause an Early-Onset Case of Dentatorubral-Pallidoluysian atrophy with novel phenotypes and a literature Review of Chinese patients.

    Fan S, Tang K, Chen J, et al.

    Gene 2024; (931()):148881 doi:10.1016/j.gene.2024.148881.

    PMID: 39181274
  2. 2

    The largest caucasian kindred with dentatorubral-pallidoluysian atrophy: A founder mutation in italy.

    Grimaldi S, Cupidi C, Smirne N, et al.

    Movement disorders : official journal of the Movement Disorder Society 2019; (34(12)):1919-1924 doi:10.1002/mds.27879.

    PMID: 31755148
  3. 3

    Pallidal degenerations and related disorders: an update.

    Jellinger KA

    Journal of neural transmission (Vienna, Austria : 1996) 2022; (129(5-6)):521-543 doi:10.1007/s00702-021-02392-2.

    PMID: 34363531
  4. 4

    Insights into Dentatorubral-Pallidoluysian Atrophy from a new Drosophila model of disease.

    Prifti MV, Nuga O, Dulay RO, et al.

    bioRxiv : the preprint server for biology 2024; doi:10.1101/2024.12.05.627083.

    PMID: 39713465
  5. 5

    Atrophin-1 antisense oligonucleotide provides robust protection from pathology in a fully humanized DRPLA model.

    Smith VL, Gidi BZ, Bragg RM, et al.

    Molecular therapy. Nucleic acids 2026; (37(1)):102815 doi:10.1016/j.omtn.2025.102815.

    PMID: 41624332
  6. 6

    DRPLA: An unusual disease or an underestimated cause of ataxia in Brazil?

    Pinto WBVR, Salomão RPA, Bergamasco NC, et al.

    Parkinsonism & related disorders 2021; (92()):67-71 doi:10.1016/j.parkreldis.2021.10.004.

    PMID: 34700111
  7. 7

    Natural History and Progression of Dentatorubral-Pallidoluysian Atrophy (DRPLA): A Retrospective Study of 22 Patients.

    Adachi H, Nishida K, Futamura N

    Movement disorders clinical practice 2025; (12(8)):1097-1104 doi:10.1002/mdc3.70088.

    PMID: 40237283
  8. 8

    Epilepsy in dentatorubral-pallidoluysian atrophy: A systematic review and meta-analysis.

    Horinouchi T, Ishibashi H, Nakagami Y, et al.

    Epilepsia 2026; (67(2)):696-711 doi:10.1111/epi.18700.

    PMID: 41147955
  9. 9

    The analysis of schizophrenia-like psychosis in dentatorubral-pallidoluysian atrophy.

    Ikegami I, Mitsuhashi Koike Y, Hayashi H, et al.

    Frontiers in neurology 2025; (16()):1564856 doi:10.3389/fneur.2025.1564856.

    PMID: 40271115
  10. 10

    Understanding dentatorubral-pallidoluysian atrophy (DRPLA) symptoms and impacts on daily life: a qualitative interview study with patients and caregivers.

    Contesse MG, Woods RJ, Leffler M, et al.

    Therapeutic advances in rare disease 2024; (5()):26330040241252447 doi:10.1177/26330040241252447.

    PMID: 38778874
  11. 11

    Establishing resources and increasing awareness to advance research on Dentatorubral-pallidoluysian atrophy toward a treatment: a patient organization perspective.

    Prades S, Compton A, Carroll JB

    Therapeutic advances in rare disease 2024; (5()):26330040241249189 doi:10.1177/26330040241249189.

    PMID: 38716233

This page about DRPLA is for informational purposes only and does not constitute medical advice. A neurologist and genetic counselor can help interpret genetic testing and plan care for your situation.

Get notified when new evidence is published on Dentatorubral pallidoluysian atrophy.

We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.